Abstract
Background: Renal impairment provides a therapeutic dilemma to the treating physician, especially when caused primary disease itself such as diabetic nephropathy. Based on data from large multi-centric clinical trials regarding the efficacy and safety in diabetics with renal impairment, certain drugs have been incorporated into standard guidelines. However, the resources in government-run tertiary care hospitals may be limited to incorporate these recommendations.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
